Financial Performance - The company achieved total operating revenue of 801.14 million yuan in 2025, representing a 122.60% increase compared to the previous year[3] - The net loss attributable to the parent company was 763.31 million yuan, a reduction of 82.65 million yuan from the previous year's loss[7] - The company's total assets increased by 74.69% to 3.00 billion yuan, while equity attributable to the parent company surged by 568.16% to 1.29 billion yuan[3] - The weighted average return on net assets improved to -73.92%, up from -161.12% in the previous year, indicating a positive trend in financial performance[3] Research and Development - Research and development expenses for the year amounted to 855.61 million yuan, reflecting the company's commitment to innovation[8] - The company is actively expanding the application potential of its commercialized products, with ongoing clinical trials for Shuwozhe® and Gaoruizhe® in NSCLC[12] Product Development and Approval - The company successfully launched two products, Shuwozhe® and Gaoruizhe®, which were included in the national medical insurance directory, significantly enhancing patient accessibility[6] - Shuwozhe® received FDA approval for treating adult patients with advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, marking a significant milestone in the company's product portfolio[9] - The company’s subsidiary obtained a drug production license, ensuring qualifications for future commercial production[12] Capital and Liquidity - The company raised 1.773 billion yuan through a private placement of shares, significantly boosting its liquidity and capital reserves[7]

Core Viewpoint - Dize Pharmaceutical reported a significant increase in revenue for 2025, with a total of 801 million yuan, representing a year-on-year growth of 122.60% [1] Financial Performance - The company achieved a revenue of 801 million yuan in 2025, which is a 122.60% increase compared to the previous year [1] - The net profit attributable to the parent company was -763 million yuan, an improvement from -846 million yuan in the same period last year [1] Product Development and Market Expansion - Two products, Shuwozhe® (generic name: Shuwotini tablets) and Gaoruizhe® (generic name: Golexini capsules), have been included in the national medical insurance drug list, enhancing patient accessibility [1] - The company is actively promoting its products and expanding market share, which has positively impacted its operations [1]

Core Viewpoint - On February 23, a total of 34 listed companies had their restricted shares unlocked, with a total market value of approximately 19.007 billion yuan [1] Group 1: Restricted Share Unlocking Details - Luzhou Laojiao (000568) had 2.0425 million shares unlocked under equity incentive restrictions - AVIC Xi'an Aircraft Industry (000768) had 4.3606 million shares unlocked under equity incentive restrictions - Hubei Energy (000883) had 19.2779 million shares unlocked under equity incentive restrictions - Jining Pharmaceutical (000919) had 1.92 million shares unlocked under equity incentive restrictions - Guangji Pharmaceutical (000952) had 2.5209 million shares unlocked under equity incentive restrictions - China Software (600536) had 57,200 shares unlocked under equity incentive restrictions - Xinhua Medical (600587) had 1.7845 million shares unlocked under equity incentive restrictions - Baoxin Software (600845) had 10.2578 million shares unlocked under equity incentive restrictions - China Railway (601390) had 55.9338 million shares unlocked under equity incentive restrictions - China Communications Construction (601800) had 5.593 million shares unlocked under equity incentive restrictions - StarNet Ruijie (002396) had 2.8342 million shares unlocked under equity incentive restrictions - Lopuskin (002333) had 22.3212 million shares unlocked under A-share issuance to legal persons - Wanbangda (300055) had 33.6538 million shares unlocked under A-share issuance to legal persons - Hangyang Co., Ltd. (002430) had 5.2049 million shares unlocked under equity incentive restrictions - Taijia Co., Ltd. (002843) had 949,600 shares unlocked under equity incentive restrictions - Nanda Optoelectronics (300346) had 130,000 shares unlocked under equity incentive restrictions - Anhui Natural Gas (603689) had 2.5064 million shares unlocked under equity incentive restrictions - Zhongyan Dadi (003001) had 97,200 shares unlocked under equity incentive restrictions - Yuanxiang New Materials (301300) had 30.2983 million shares unlocked with extended lock-up period - Yidao Information (001314) had 88.6187 million shares unlocked under pre-issuance restrictions - Tongda Electric (603390) had 579,500 shares unlocked under equity incentive restrictions - Yangzhou Jinqiao (603307) had 50 million shares unlocked under pre-issuance restrictions - Aili Home (603221) had 2.29 million shares unlocked under equity incentive restrictions - Zhili Fang (301312) had 333,900 shares unlocked under equity incentive restrictions - Kuntai Co., Ltd. (001260) had 83.25 million shares unlocked under pre-issuance restrictions - Entropy Technology (301330) had 92.5223 million shares unlocked with extended lock-up period - Yatong Precision (603190) had 596,100 shares unlocked under pre-issuance restrictions - Sanwang Communication (688618) had 87,400 shares unlocked - Longxun Co., Ltd. (688486) had 30.6312 million shares unlocked - Dize Pharmaceutical (688192) had 991,100 shares unlocked - Haohan Depth (688292) had 57.5177 million shares unlocked - Haizheng Biomaterials (688203) had 78.5601 million shares unlocked - Diaomicro (688381) had 55.9536 million shares unlocked - Zhongrun Optics (688307) had 29.8507 million shares unlocked [1]

Core Viewpoint - The article discusses the current funding logic in the market, highlighting the significant movements of public funds in the technology sector, particularly in the semiconductor and biopharmaceutical industries, as they adjust their portfolios based on performance and valuation metrics [3][8]. Group 1: Public Fund Movements - Public funds have shown a notable shift in their holdings, particularly in the STAR Market, with the STAR 50 Index rising by 12.1% this year [3][4]. - The total market capitalization of STAR Market companies reached 10.4 trillion yuan, with the technology sector dominating, accounting for 62.1% of the total market cap [5][6]. - The semiconductor industry remains the core focus for fund allocation, with 12 companies in the sector having a market capitalization exceeding 10 billion yuan [9][11]. Group 2: Semiconductor Sector Insights - The market's pricing anchor for the semiconductor sector has shifted from "valuation expansion" to "performance realization," emphasizing the importance of actual earnings [13][14]. - Key drivers for future growth in the semiconductor sector include strong order backlogs, profit growth through acquisitions and expansions, and sustained price increases in advanced processes [13][14]. - Public funds have significantly increased their holdings in semiconductor materials, chip design, and equipment, with companies like ShenGong Co. seeing an 11% increase in fund holdings [15][21]. Group 3: Biopharmaceutical Sector Insights - The biopharmaceutical sector is a critical area for public funds, with major holdings in companies like BeiGene and United Imaging Healthcare, although the sector has faced a reduction in holdings for several key companies [24][26]. - The article notes that innovative drug companies are currently under pressure, with significant reductions in holdings observed in companies like BaiLi TianHeng and RongChang Biopharma [26][28]. - Despite the challenges, companies with strong earnings potential and innovative drug pipelines are still attracting interest from public funds, indicating a selective investment approach [35][40].

Core Viewpoint - The keyword for the stock market in 2025 is expected to be "innovative drugs," with significant stock price increases driven by the potential of in-development innovative drugs and BD (business development) transactions rather than traditional revenue from already marketed drugs [1] Group 1: BD Transactions - In 2025, China's innovative drug BD transaction total exceeded $100 billion, with notable orders reaching $10 billion, and upfront payments from multinational pharmaceutical companies reaching a new high of $1.25 billion [1] - Landmark transactions include a $13 billion collaboration between Qihuang Dejian and Biohaven/AimedBio in January, marking a milestone for China's ADC technology [2] - In May, 3SBio's deal with Pfizer exceeded $6 billion, setting a record for upfront payments in China at $1.25 billion, highlighting the value of both first-in-class and fast-follow drugs [2] - In July, a $12 billion strategic partnership between Hengrui Medicine and GlaxoSmithKline showcased the depth of early-stage pipelines in leading Chinese pharmaceutical companies [2] - In October, Innovent Biologics and Takeda's collaboration worth $11.4 billion included a cost-sharing model for global R&D, enhancing operational capabilities for future international ventures [2] Group 2: Milestone Payments and Emerging Fields - Several past BD transactions reached milestone payments in 2025, including a $300 million payment to China National Pharmaceutical's subsidiary from Merck and a $250 million payment to Bairui Tianheng from Bristol-Myers Squibb [3] - The focus of BD transactions is shifting from oncology to other therapeutic areas, with autoimmune diseases, metabolism, and central nervous system disorders emerging as new hot fields [3] - Notable deals include the global rights licensing of BTK inhibitor Orelabrutinib for multiple sclerosis by Nocera Biopharma, with a potential total transaction value exceeding $2 billion [3] - The metabolic field is gaining traction, driven by global weight loss trends, with several companies entering into licensing agreements for GLP-1 targeted drugs [3] Group 3: Independent Clinical Trials and Regulatory Approvals - Numerous innovative drug companies in China are advancing their own overseas clinical trials, achieving significant progress [4] - In early 2025, Dize Pharmaceutical's lung cancer targeted drug received priority review from the FDA and was approved in July, becoming the first globally innovative drug independently developed in China to gain approval in the U.S. [4] - Other advancements include breakthrough therapy designations for CS0159 by Kexi Kedi and a Phase III trial approval for a recombinant human albumin injection by Heyuan Biopharma [4] - These developments indicate that the Chinese innovative drug industry is becoming a significant force in global innovation, transitioning from fast-following to original innovation and integrating deeply into the global value chain [4]

Group 1 - The core focus events for Dize Pharmaceutical in 2026 and beyond include the progress of H-share listing, key milestones in the R&D pipeline, annual business plan review, and commercialization and market expansion [1] - Dize Pharmaceutical submitted its H-share listing application to the Hong Kong Stock Exchange on January 23, 2026, aiming for a dual listing in Hong Kong to enhance its global strategy and attract international investors [2] - The company plans to advance multiple core products into clinical data update stages in 2026, including the global multi-center Phase III study of Shuwotai (Shuwotai) for EGFR Exon20ins non-small cell lung cancer, which has completed patient enrollment [3] Group 2 - Dize Pharmaceutical plans to hold a board meeting in 2026 to review the annual sales plan, which is yet to be finalized and will be disclosed after board approval [4] - The company aims to leverage the inclusion of core products Shuwotai and Guaizhe in the national medical insurance catalog to deepen domestic market coverage and promote overseas commercialization in 2026 [5] - The sales expense ratio decreased to 72% in the first three quarters of 2025, and the company plans to further enhance operational efficiency in 2026 [5]

Core Viewpoint - The refinancing market is undergoing targeted adjustments with the introduction of new policies aimed at supporting high-quality and innovative companies, simplifying processes, and preventing risks [1] Group 1: Refinancing Policy Adjustments - The new refinancing policy reduces the interval for companies that are unprofitable and meet specific criteria from 18 months to 6 months, allowing them to initiate new rounds of refinancing more quickly [2] - Companies in the high-tech sector express that the new policy will facilitate continuous funding for product development and commercialization, thus supporting their growth [2] Group 2: Support for Underperforming Companies - The new policy allows companies that have experienced stock price declines to engage in refinancing through methods such as private placements and convertible bonds, provided the funds are directed towards their main business [4] - As of February 10, there are 553 companies listed on the exchanges that are currently underperforming, indicating a significant potential for these companies to leverage the new refinancing options [4] Group 3: Expansion of Fund Utilization - The new policy encourages high-quality companies to allocate funds towards new industries, business models, and technologies that align with their main operations, thus promoting a second growth curve [6] - This shift from strict limitations on fund allocation to a more flexible approach is expected to enhance capital flow into high-tech industries and improve resource allocation efficiency [6]

Group 1 - The company Dize Pharmaceutical announced that approximately 991,000 restricted shares will be unlocked and become tradable on February 24, 2026 [1] Group 2 - The central bank, which has been the largest buyer of gold for two consecutive years, aims to accumulate 700 tons of gold and has announced an additional purchase of 150 tons [1]

Core Viewpoint - The announcement from Dize Pharmaceutical details the second tranche of the employee stock option plan, which involves the release of 991,073 shares, representing 0.21% of the company's total share capital [1] Group 1 - The shares being released are part of the 2020 employee stock option plan, specifically the second exercise period [1] - A total of 105 shareholders are involved in this share release [1] - The shares were registered on February 16, 2023, with a lock-up period of 36 months, set to be tradable starting February 24, 2026 [1] Group 2 - The company's total share capital has changed due to previous equity incentive plans and targeted issuances, currently standing at 464,633,342 shares as of the announcement date [1]

本次股票上市流通日期为2026 年 2 月 24 日。 证券代码：688192 证券简称：迪哲医药 公告编号：2026-008 迪哲（江苏）医药股份有限公司 关于 2020 年员工股份期权计划第二个行权期第二次行 权限售股上市流通公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为股权激励股份；股票认购方式为网下，上 市股数为991,073股。 本次股票上市流通总数为991,073股。 | 序 | 股份变动 | | 股份变动事项 | 股份变动数量 | 公告索引 | | --- | --- | --- | --- | --- | --- | | 号 | 时间 | | | （股） | | | 1 | 2024 | 年 2 | 2022 年度限制性 | 3,550,000 | 《2022 年度限制性股票 | | | 月 5 | 日 | 股票激励计划首 | | 激励计划首次授予部分 | | | | | 次授予部分第一 | | 第一类激励对象第一个 | | | | | 类激励对象第一 | | 归属 ...